(Q37004638)

17 August 2017

Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity (English)

1 reference

17 August 2017

1 reference

Shawna L Bull Phelps

1

1 reference

17 August 2017

Juliet Carbon

2

1 reference

17 August 2017

Andrew Miller

3

1 reference

17 August 2017

Emely Castro-Rivera

4

1 reference

17 August 2017

Shanna Arnold

5

1 reference

17 August 2017

Rolf A Brekken

6

1 reference

17 August 2017

Jayanthi S Lea

7

1 reference

17 August 2017

language of work or name

English

0 references

publication date

6 November 2008

1 reference

American Journal of Obstetrics and Gynecology

17 August 2017

1 reference

17 August 2017

200

1 reference

17 August 2017

2

1 reference

17 August 2017

180.e1-7

1 reference

Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

SPARC and tumor growth: where the seed meets the soil?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Development of a syngeneic mouse model for events related to ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

The myth of measurable disease in ovarian cancer.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

SPARC deficiency leads to early-onset cataractogenesis.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3709016

Cellular and molecular determinants of cisplatin resistance

4 September 2018

1 reference

12 December 2020

Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer

1 reference

12 December 2020

SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions

1 reference

12 December 2020

Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells

1 reference

12 December 2020

10.1016/J.AJOG.2008.08.047

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

18992864

1 reference